As Founder, Chairman and CEO of Intra-Cellular Therapies (ITCI), Dr. Mates leads Intra-Cellular Therapies, a biopharmaceutical company developing novel treatments that harness Nobel-prize winning science that broadens the way scientists understand how therapeutics affect the intra-cellular signaling of neurons and other cells. This vital work helps drive the development of new treatments for schizophrenia and other neuropsychiatric conditions.
Dr. Mates has more than 25 years of experience leading public and private companies with a steadfast commitment to cutting-edge science and research to discover innovative approaches to treating disease. Prior to co-founding ITCI in 2002, she was President and board member of North American Vaccine Inc. and its predecessor companies for almost a decade, during which time she oversaw the development and approval of pediatric vaccines. Throughout her career, she has held numerous advisory and board positions including a current board appointment to Biotechnology Innovation Organization Emerging Company Section (BIO ECS). Previous appointments include chairman of the New York Biotechnology Association, Board of Visitors of the Biotechnology Institute of the University of Maryland, and member of the Harvard School of Public Health Advisory Council of the Center for Society and Health.
Dr. Mates received her B.S from The Ohio State University and her Ph.D. from the University of Washington. She completed her postdoctoral fellowships at the Massachusetts General Hospital and Harvard Medical School.